scholarly journals Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature

Oncotarget ◽  
2016 ◽  
Vol 7 (38) ◽  
pp. 62533-62546 ◽  
Author(s):  
Jaeyun Jung ◽  
Cue Hyunkyu Lee ◽  
Hyang Sook Seol ◽  
Yeon Sook Choi ◽  
Eunji Kim ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Molecular Characterization ◽  
Pancreatic Cancer Patient

Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report

2021 ◽  
pp. 1-7
Author(s):  
Janna-Lisa Velthaus ◽  
Peter Iglauer ◽  
Ronald Simon ◽  
Carsten Bokemeyer ◽  
Peter Bannas ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Point Mutation ◽  
Kinase Inhibitors ◽  
Point Mutations ◽  
Progression Free Survival ◽  
Pancreatic Cancer Patient ◽  
Targeted Treatment ◽  
Precision Oncology ◽  
Disease Stabilization

<b><i>Introduction:</i></b> The prognosis of pancreatic cancer has improved only modestly in recent years. This is partly due to the lack of development in precision oncology including immune oncology in this entity. Rearrangements of the proto-oncogene tyrosine protein kinase <i>ROS1</i> gene represent driver alterations found especially in lung cancer. Tyrosine kinase inhibitors (TKI) with activity against ROS1 including lorlatinib substantially improved the outcome of this patient population. Anecdotal evidence reports treatment of pancreatic cancer harboring <i>ROS1</i> fusions with ROS1 TKI, but data concerning treatment of patients with <i>ROS1</i> point mutations are lacking. <b><i>Case Presentation:</i></b> This case describes a pancreatic cancer patient harboring a <i>ROS1</i> point mutation that occurred without an underlying <i>ROS1</i> rearrangement and thus not in the resistance situation. The heavily pretreated patient showed a strong decrease of the tumor biomarkers (CA19-9 and CEA) and radiologically a durable stable disease to the targeted treatment with lorlatinib, thereby achieving a progression-free survival of 12 months. <b><i>Conclusion:</i></b> Our data are the first to show a clinical benefit from targeted treatment with ROS1 TKI in a cancer patient with a thus far undescribed <i>ROS1</i> point mutation without a concomitant <i>ROS1</i> rearrangement. Furthermore, they indicate that <i>ROS1</i> could be an oncogenic driver in pancreatic cancer. This subgroup could be eligible for targeted treatments, which may contribute to the urgently needed improvement in patient outcome.

scholarly journals hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

2011 ◽  
Vol 60 (6) ◽  
pp. 809-818 ◽  
Author(s):  
Else M. Inderberg Suso ◽  
Svein Dueland ◽  
Anne-Marie Rasmussen ◽  
Turid Vetrhus ◽  
Steinar Aamdal ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Dendritic Cell ◽  
Cancer Patient ◽  
Complete Response ◽  
Pancreatic Cancer Patient ◽  
Dendritic Cell Vaccination ◽  
Htert Mrna

scholarly journals Factors Associated with Ketamine Use in Pancreatic Cancer Patient in a Single Hospice Center

2016 ◽  
Vol 19 (3) ◽  
pp. 249-255
Author(s):  
Kyung Min Kwon ◽  
Yong Joo Lee ◽  
Chang Jin Choi ◽  
Chul Min Kim ◽  
Jo Hi Yoon ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Pancreatic Cancer Patient ◽  
Factors Associated

The effect of pancreatic cancer patient derived serum on macrophage M1/M2 polarization

Pancreatology ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. S147-S148 ◽  
Author(s):  
Matilda Juusola ◽  
Harri Mustonen ◽  
Sanna Vainionpää ◽  
Markus Vähä-Koskela ◽  
Pauli Puolakkainen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Pancreatic Cancer Patient ◽  
M2 Polarization
Sign in / Sign up

Export Citation Format

Share Document